This study aimed to evaluate the effectiveness of physical exercise in patients with prostate cancer. The study concluded that physical exercise is associated with reduction of tiredness, and improving functional capacity and quality of life in these patients.

This study reviewed the current NCCN guidelines for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

This study investigated if people with nocturia (waking up at night to urinate) can take desmopressin acetate (Noctiva) medication. Researchers suggested that desmopressin may increase the risk of side effects in older adults with other medical conditions taking many medications.

This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity.

This study examined the effects of abiraterone acetate (AA; Zytiga) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that AA and ADT combination improves the outcomes in these patients.

The study summarized the outcomes of bisphosphonates and RANKL-inhibitors as supportive treatment in men with prostate cancer (PC) and bone metastases (BM). The authors recommended that a balance between the efficacy and safety of such therapies must be considered for preventing skeletal events in such patients.

This study compared the effectiveness of giving androgen deprivation therapy (ADT) before or after radiotherapy (RT) for prostate cancer (PCa). The study found that treatment with RT followed by ADT increased patient survival without the spread of the disease.

This study investigated the quality of life after treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) with enzalutamide (Xtandi) in combination with hormone therapy. The study found that enzalutamide + hormone therapy improved the quality of life of patients, compared to hormone therapy alone.

This study investigated the benefit of an orally-disintegrating desmopressin (OD-DP; Minirin) tablet in nocturia caused by nocturnal polyuria (NP). They found that OD-DP tablets improved NP symptoms. 

This review summarized clinical guidelines for treating prostate cancer (PC) recommended by the European Society for Medical Oncology (ESMO). The main recommendation was that all therapies should be risk-based and personalized.